Drug intelligence / Profile preview

4ET2124

Development stage: Preclinical
Lead developer: 4E Therapeutics
Modality: Small Molecules

Overview

4ET2124 is a small molecule drug candidate developed by 4E Therapeutics for the treatment of migraine. It acts as a peripherally restricted inhibitor of mitogen-activated protein kinase interacting kinase (MNK), targeting pain signaling pathways outside the central nervous system to reduce migraine symptoms while minimizing CNS-related side effects. The compound has completed preliminary in vitro safety studies and is ready to begin IND-enabling studies. Its mechanism offers an alternative to opioid-based therapies, aiming for improved efficacy and safety in migraine management[1][2].

Targets

MKNK1 (Mitogen‑activated protein kinase‑interacting serine/threonine-protein kinase 1)

Beyond the preview

Go deeper on 4ET2124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4ET2124.

Explore the full profile